Vera Therapeutics (VERA) reported $714.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which combined with availability under its debt facility, Vera Therapeutics believes to be sufficient to fund operations through potential approval and U.S. commercial launch of atacicept and beyond.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics appoints Skelton as Chief Commercial Officer
- Buy Rating on Vera: De-Risked Atacicept Approval Path and Large IgA Nephropathy Market Drive Compelling Upside into 2026 Catalysts
- Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA
- Wolfe upgrades Vertex Pharmaceuticals, says ‘may be due for a rebound’